放射增敏剂
超分子
放射治疗
癌症研究
癌症
体内
敏化
纳米技术
化学
生物物理学
材料科学
医学
生物
免疫学
遗传学
内科学
分子
有机化学
作者
Jing Wang,Jing Zhao,Fang Ma,Liuyun Gong,Yinliang Lu,Weiping Xiao,Hanmin Tang,Chengyi Gao,Yuetong Chen,Jun Ma,Zhan Gao,Jin Yan,Suxia Han
出处
期刊:Small
[Wiley]
日期:2022-12-09
卷期号:19 (11)
被引量:10
标识
DOI:10.1002/smll.202204238
摘要
Abstract Over half of cancer patients are subjected to radiotherapy, but owing to the deficient amount of reactive oxygen radicals (ROS) and DNA double‐strand breaks (DSBs), a fair number of them suffer from radiotherapy resistance and the subsequent short‐term survival opportunity. To overcome it, many successes have been achieved in radiosensitizer discovery using physical strategy and/or biological strategy, but significant challenges remain regarding developing clinically translational radiosensitizers. Herein, a peptide‐Au(I) infinite coordination supermolecule termed PAICS is developed that combined both physical and biological radiosensitization and possessed pharmaceutical characteristics including adequate circulatory stability, controllable drug release, tumor‐prioritized accumulation, and the favorable body eliminability. As expected, monovalent gold ion endowed this supermolecule with high X‐ray absorption and the subsequent radiosensitization. Furthermore, a peptide targeting CRM1, is assembled into the supermolecule, which successfully activates p53 and apoptosis pathway, thereby further sensitizing radiotherapy. As a result, PAICS showed superior ability for radiotherapy sensitization in vivo and maintained a favorable safety profile. Thus, the PAICS reported here will offer a feasible solution to simultaneously overcome both the pharmaceutical obstacles of physical and biological radiosensitizers and will enable the development of a class of nanomedicines for tumor radiotherapy sensitization.
科研通智能强力驱动
Strongly Powered by AbleSci AI